Showing 3751-3760 of 7602 results for "".
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Aerolase Appoints Industry Vet Didier Leclercq to Leadership Teamhttps://practicaldermatology.com/news/aerolase-appoints-industry-vet-didier-leclercq-to-leadership-team/2460448/Didier Leclercq is Aerolase’s new Vice President of Global Market Development. Prior to his role as Managing Director of the SHIELD innovation center of Nestlé Skin Health/Galderma, Mr. Leclercq ran Q-Med once it was acquired by G
- Ortho Dermatologics Launches Arazlo Lotion in the UShttps://practicaldermatology.com/news/ortho-dermatologics-launches-arazlo-lotion-in-the-us/2460447/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics launched Arazlo (tazarotene) Lotion, 0.045%. Now available commercially to health care professionals in the US, it was FDA approved in December 2019 as the first tazaroten
- Arcutis: Enrollment Complete for Phase 2 Study of Roflumilasthttps://practicaldermatology.com/news/arcutis-enrollment-complete-for-phase-2-study-of-roflumilast/2460446/Enrollment is now complete for the Phase 2 proof of concept clinical trial evaluating roflumilast foam for the treatment of seborrheic dermatitis. Arcutis Biotherapeutics is developing roflumilast, a selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor), in a once-daily topical
- FDA Approves Merck’s Keytruda for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Not Curable by Surgery or Radiationhttps://practicaldermatology.com/news/fda-approves-mercks-keytruda-for-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma-not-curable-by-surgery-or-radiation/2460445/The FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in both three and six week dosing options as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
- FDA Approves New Dupixent Pre-filled Pen Designed to Support More Convenient Self-Administrationhttps://practicaldermatology.com/news/fda-approves-new-dupixent-pre-filled-pen-designed-to-support-more-convenient-self-administration/2460444/The FDA has approved a 300mg single-dose pre-filled pen for Regeneron Pharmaceuticals, Inc. and Sanofi's Dupixent (dupilumab). The pre-filled pen is approved for all Dupixent indications in patients aged 12 years and older, which includes use in certain patients with atopic dermatitis, asthma
- Acne News: Clascoterone Cream 1% Exhibits Long-Term Safety for Treatment of Acnehttps://practicaldermatology.com/news/acne-news-clascoterone-cream-1-exhibits-long-term-safety-for-treatment-of-acne/2460442/Cassiopea SpA’s Clascoterone cream 1% is safe for the treatment of acne with low rates of treatment-related adverse events, according to a study in the online issue of
- Tralokinumab Achieves Primary and Secondary Endpoints in Three pivotal Phase 3 Trials for ADhttps://practicaldermatology.com/news/tralokinumab-achieves-primary-and-secondary-endpoints-in-three-pivotal-phase-3-trials-for-ad/2460440/LEO Pharma A/S, shared results showing that tralokinumab 300mg, administered subcutaneously every two weeks, demonstrated efficacy and safety with or without concomitant use of a topical corticosteroid (TCS) in three Phase 3 trials (ECZTRA 1-3) for the treatment of adults with moderate to severe
- Abbvie's RINVOQ Improves Skin Clearance and Itch in First Phase 3 Study for ADhttps://practicaldermatology.com/news/abbvies-rinvoq-improves-skin-clearance-and-itch-in-first-phase-3-study-for-ad/2460439/AbbVie’s RINVOQ (upadacitinib) performed well in Measure Up 1, the first Phase 3 study to evaluate its efficacy and safety for the treatment of moderate-to-severe atopic dermatitis. Full results from Measure Up 1 will be presented at a future medical meeting and published in a pee
- Label Update: Low Risk of Antibiotic Resistance with Almirall's Seysarahttps://practicaldermatology.com/news/label-update-low-risk-of-antibiotic-resistance-with-seysara/2460437/The FDA approved a label update for Almirall's Seysara stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline. This information is included in the Microbiology Section (12.4) of the prescribing information.</